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Background: The proteasome is a large multicatalytic protease complex
(700 kDa) involved in a number of highly regulated processes. It has three major
catalytic activities: a chymotrypsin-like activity, a trypsin-like activity and a post-
glutamyl peptide hydrolyzing (PGPH) activity. To be useful as molecular probes,
which could help dissect the cellular functions of the proteasome, inhibitors
should be specific for the proteasome, active in vivo and selectively block only
one of the three catalytic activities. To date, few inhibitors fulfill these
requirements so we set out to make novel proteasome inhibitors that
incorporate these characteristics. 
Results: A panel of amino-terminally acetylated peptide α′,β′-epoxyketones with
leucine in P1 and various aliphatic or aromatic amino acids in P2–P4 were
prepared and evaluated. Most compounds selectively inhibited the
chymotrypsin-like activity, while only weakly inhibiting the trypsin-like and PGPH
activities. After optimization, one inhibitor, Ac-hFLFL-epoxide, was found to be
more potent and selective for the inhibition of the chymotrypsin-like activity than
several previously described inhibitors. This inhibitor also exhibited strong in
vivo anti-inflammatory activity. 
Conclusions: Optimization of amino-terminally acetylated peptide
α′,β′-epoxyketones furnished a potent proteasome inhibitor, Ac-hFLFL-epoxide,
that has an excellent selectivity for the chymotrypsin-like activity. The inhibitor
also proved to be a potent antiproliferative and anti-inflammatory agent. The
strong in vivo and in vitro activities suggest that this class of proteasome
inhibitors could be both molecular probes and therapeutic agents.
Introduction
Eukaryotic cells contain substantial amounts of a large
proteolytic complex called the proteasome, which is
widely recognized as the central proteolytic machinery
required for nonlysosomal ubiquitin-dependent protein
degradation [1]. General housekeeping functions of the
proteasome include removal of improperly assembled or
misfolded proteins formed as a result of mutation, heat or
oxidative stress [2]. The proteasome is also responsible for
protein degradation in highly regulated processes includ-
ing cell-cycle progression [3], inflammatory responses,
such as NF-κB activation [4], and antigen processing [5]. 
The catalytic core of the proteasome of eukaryotic cells
comprises the 20S cylindrical part, consisting of 28 sub-
units forming four stacked rings [6,7]. The two central
rings each contain three catalytically active β subunits that
hydrolyze their substrates by a unique mode of action
[6–8]. During assembly of the proteasome, cleavage of
amino-terminal prosequences liberates amino-terminal
threonines whose hydroxyl groups act as nucleophiles in
the catalytic step. The two outer rings are noncatalytic and
the seven α subunits in each ring serve as an anchor for
the 19S (PA700) or 11S (PA28) regulatory particles [9,10]
that cap each end to form the fully assembled proteasome.
Higher vertebrates can express a γ-interferon-inducible
immuno-proteasome, in which the β subunits X, Y and Z
are replaced by LMP7, LMP2 and MECL1, respectively.
This substitution results in altered proteolytic activities
producing peptides with sequence motifs suitable for
binding by MHC class I molecules [5]. The multiple cata-
lytic subunits of the 20S proteasome exhibit three major
activities: a chymotrypsin-like activity that cleaves sub-
strates after large hydrophobic residues, a trypsin-like
activity that hydrolyzes bonds after basic amino acids, and
a post-glutamyl peptide hydrolyzing (PGPH) activity that
cleaves after acidic residues [11]. Two less well-character-
ized catalytic activities have also been ascribed to the pro-
teasome: BrAAP, which cleaves after branched-chain
amino acids, and SNAAP, which cleaves after small
neutral amino acids [11].
Proteasome inhibitors are valuable tools that enable the
elucidation of details in cellular events regulated by the
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proteasome [12]. In addition, inhibitors have potential
therapeutic applications and use in mechanistic studies of
the proteolytic machinery of the proteasome [12–14]. To
date, several classes of proteasome inhibitors, for example
the natural product lactacystin [15], peptide aldehydes
[16–19], peptide α′,β′-epoxyketones [20–23], peptide gly-
oxals (α-keto aldehydes) [24], peptide vinyl sulfones
[18,25,26] and peptide boronic acids [16,18], have been
described. For an inhibitor to be useful as a molecular
probe or therapeutic agent it should preferably be both
potent and selective for inhibition of the proteasome. Fur-
thermore, for use in cell culture or animal model studies,
properties such as cell-membrane permeability and
bioavailability should be considered. Although peptide
aldehydes, which reversibly and covalently inhibit the
proteasome, are among the most well-studied compounds
so far, they also inhibit other proteases such as cathepsins
and calpains [1,17]. This lack of specificity also holds true
for peptide vinyl sulfones, which covalently inactivate
both the proteasome [26] and intracellular cysteine pro-
teases such as cathepsins and calpains [26,27]. The active
form of lactacystin, clasto-lactacystin β-lactone, is also
known to inhibit cathepsin A [28] and tripeptidyl pepti-
dase II [29], in addition to the three catalytic activities of
the proteasome [30]. Peptide boronic acids, a promising
class of covalently inactivating and reversible proteasome
inhibitors, show high selectivity for the proteasome over
other proteases [16]. Recently bifunctional inhibitors,
homodimeric or heterodimeric peptide aldehydes and
maleimide-containing peptide aldehydes with improved
potency and subunit selectivity have been described
[31,32]. Although they are useful for in vitro investigations
of the proteasome, their potential in cell-based systems
might be limited.
Recent efforts in our lab have centered on the identifica-
tion of the cellular targets of the microbial antitumor
natural products epoxomicin [33] and eponemycin [34]
(Figure 1). Biotinylated derivatives of epoxomicin [21] and
dihydroeponemycin [35] (dihydroeponemycin retains the
biological activity of eponemycin) were found to bind
covalently and irreversibly to catalytic subunits of the pro-
teasome [22,23]. Epoxomicin was found to bind X, LMP7,
Z and MECL1 [22], whereas dihydroeponemycin showed
selectivity for LMP2, X and LMP7 [23]. Moreover, epox-
omicin is highly selective for the proteasome, and causes
cell morphology change and growth arrest, leading to apop-
tosis [22]. In addition to the previously described antitu-
mor activity, epoxomicin also exhibits anti-inflammatory
activity in mice, presumably by inhibition of NF-kB activa-
tion [22]. Peptide α′,β′-epoxyketones [20–23] are emerging
as an important class of inhibitors with promise both as
molecular probes and therapeutic agents. 
Our ongoing efforts are aimed at the design and synthesis
of novel, more potent inhibitors with improved in vivo
activity. Moreover, the ultimate goal is to develop
inhibitors selective for each of the three major proteolytic
activities of the proteasome. The use of subunit-specific
inhibitors that covalently and irreversibly bind to the
active sites would result in ‘chemical knock-outs’, which
would allow the dissection of the proteasome function
using a chemical genetics approach [36].
In this report we describe the synthesis of a series of
peptide α′,β′-epoxyketones of varied length and amino
acid sequence. These compounds were characterized for
their ability to inhibit proteasomal enzymatic activity and
cell growth. Furthermore, one inhibitor, which was opti-
mized for inhibition of the chymotrypsin-like activity,
exhibited strong anti-inflammatory activity in vivo. 
Results and discussion
Design and synthesis of peptide α′,β′-epoxyketones
Catalytic subunits of the 20S proteasome accommodate
various sidechains of the peptide substrate within multi-
ple pockets on both sides of the scissile amide bond, as
shown schematically in Figure 2. In addition to the key
role that the P1 residue plays in subunit binding and
hydrolysis, the overall length and substrate sequence con-
tribute to defining the cleavage rate and pattern. In an
analogous manner, length and sequence of inhibitors also
strongly influence potency and selectivity for the three
major catalytic activities of the proteasome. Inhibitors that
have hydrophobic residues such as leucine and phenylala-
nine in P1 generally show high selectivity for the chymo-
trypsin-like activity [16,22,24,25,31], whereas basic
residues such as lysine and arginine favour the inhibition
of the trypsin-like activity [31]. Recent reports, however,
indicate that variation in length and of residues in P2–P4
of inhibitors with a hydrophobic sidechain in P1 can affect
812 Chemistry & Biology 1999, Vol 6 No 11
Figure 1
Structure of epoxomicin and eponemycin, two antitumor natural
products that potently inhibit the proteasome.
N
N
H
H
N
N
HO
O
O
O
O
O
OH
H
N
N
H
OH
O OH
O
O
O
Epoxomicin
Eponemycin Chemistry & Biology
the potency and subunit selectivity [16,24,25]. For
example, introducing large hydrophobic sidechains in P4
of peptide vinyl sulfone inhibitors influences both
potency and subunit selectivity [25], suggesting that
sequence variation can be used to enhance subunit selec-
tivity. Moreover, dihydroeponemycin (compare with
eponemycin, Figure 1) shows no selectivity for the chymo-
trypsin-like activity over the PGPH activity, despite a
leucine sidechain in P1 [23]. With the aim of designing
potent inhibitors that have strong in vivo activity, it is
likely that amino acids with hydrophobic sidechains in all
positions as well as a N-acylated amino terminus would
increase cell permeability and resistance to amino pepti-
dases. We therefore focused on introducing different
hydrophobic amino acids at P2–P4 of N-acetylated peptide
α′,β′-epoxyketones with a leucine sidechain at P1 in order
to provide important information on the structural features
of proteasome inhibitors governing subunit selectivity and
in vivo activity.
The peptide α′,β′-epoxyketones (compounds 1–18 in
Tables 1–4) were assembled from left-hand peptide frag-
ments (Figure 3a), prepared by standard solid-phase synthe-
sis [37,38], and the previously described α′,β′-epoxyketone
derived from leucine (Figure 3b) [21]. Variation in the size
of sidechains in P2–P4 was accomplished by the use of
alanine, leucine, phenylalanine, homophenylalanine, 3-(1-
naphthyl)-alanine and p-benzoylphenylalanine as building
blocks in the solid-phase peptide syntheses. Initially, the
couplings between the left- and right-handed fragments
(Figure 3) were carried out with O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HATU)
[39] and diisopropylethylamine (DIEA) in dimethylfor-
mamide (DMF). When the products were analyzed using
1H-nuclear magnetic resonance (NMR), however, some
signals, most notably the signals from the hydrogens on C-1
of the epoxide, appeared in duplicate. The additional set of
signals most likely originate from a minor stereoisomer
(5–30%) formed by epimerization of the α carbon during
the segment coupling (Figure 3). The minor epimers were
difficult to remove using standard chromatography and poor
overall yields were generally obtained. This undesired side
reaction could be reduced but not eliminated by employing
mixtures of DMF and dichloromethane as solvent and by
using 2,4,6-trimethylpyridine (collidine) as base [40]. Purifi-
cation using preparative normal phase high-performance
liquid chromatography (HPLC) furnished the target
peptide α′,β′-epoxyketones in good purity (typically >95%)
and modest to good yields (20–70%).
Effect of the inhibitor length on inhibition of three catalytic
activities of the 20S proteasome
As a first step, we investigated the potency of inhibitors of
varying length. Mono-, di-, tri- and tetraleucine epoxides
(compounds 1–4, Table 1) were ranked by determining
the kobs/[I] value (Table 1) for inhibition of the chy-
motrypsin-like, trypsin-like and PGPH activities of puri-
fied bovine erythrocyte 20S proteasome. Tetrapeptide 1
showed strong inhibition of the chymotrypsin-like activity
and had essentially no effect on the trypsin-like and
PGPH activities. Truncation by one residue to give the
tripeptide 2 resulted in a significantly reduced inhibition
of the chymotrypsin-like activity with a small increase in
the inhibition of the PGPH activity. Dipeptide 3 and the
amino acid derivative 4 were found to be inactive against
all three catalytic activities. Epoxomicin (Figure 1) is a
very potent inhibitor of the chymotrypsin-like activity,
Research Paper  Subunit-specific proteasome inhibitors Elofsson et al. 813
Figure 2
The catalytic sites of the proteasome accommodate multiple amino acid
sidechains of the peptide substrate on both sides of the scissile bond.
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Synthesis of peptide α′,β′-epoxyketones by coupling of (a) peptide left-hand fragments to (b) the α′,β′-epoxyleucine right-hand fragment.
whereas dihydroeponemycin (compare with eponemycin,
Figure 1), which lacks a P4 residue, shows modest inhibi-
tion of the same activity [22,23]. Taken together, these
findings and the data in Table 1 suggest that the presence
of a residue in P4 is important for strong inhibition of the
chymotrypsin-like activity by peptide α′,β′-epoxyketones
with a leucine sidechain in P1. This is in agreement with a
recent study in which tripeptide vinyl sulfones were found
to be less potent than tetrapeptide vinyl sulfones for inhi-
bition of all three catalytic activities [25]. 
The tetraleucine epoxide 1 was chosen as a reference
compound for the continuation of this study, in which the
leucine residues in P2–P4 were substituted by different
amino acids with aliphatic or aromatic sidechains of
varying size.
Effect of amino acid substitutions in P2, P3 and P4 on
inhibition of the three catalytic activities of the 20S
proteasome
The leucine residues in P2 and P3 of the tetraleucine
inhibitor 1 were substituted with alanine, phenylalanine or
3-(1-naphtyl)-alanine to give compounds 5–10, respectively
(Table 2). Compounds with aromatic sidechains in P2 and
P3 increased the reactivity against the chymotrypsin-like
activity with phenylalanine being optimal for P2 (com-
pound 6) and 3-(1-naphthyl)-alanine for P3 (compound 10).
Introduction of a phenylalanine residue in P2 furnished a
highly potent inhibitor 6 with a kobs/[I] value exceeding the
value previously reported for epoxomicin (Table 4) [22]. A
recent study indicated a similar trend for dipeptide and
tripeptide aldehydes and boronic acids where aromatic
sidechains in P2 and P3 resulted in powerful inhibitors of
the chymotrypsin-like activity [16]. 
The small and neutral alanine sidechain in P2 and P3
(compounds 5 and 8) appears to be beneficial for inhibi-
tion of the trypsin-like and PGPH activity. The kobs/[I]
values are relatively low, which make general predictions
regarding sidechain size in P2 and P3 and inhibition of the
trypsin-like and PGPH activities uncertain. Compound 8,
which has an alanine residue in P3, is, however, more
potent for inhibition of the PGPH activity than, for
example, the previously reported compounds epoxomicin
[22], eponemycin [23], 4-hydroxy-2-iodo-5-nitrophenyl-
acetyl-leucinyl-leucinyl-leucine vinyl sulfone (NLVS)
[25], and clasto-lactacystin β-lactone [15] (Table 4). The
boronic acid PS-341 [16] (Table 4) is, however, by far the
most potent inhibitor of the PGPH activity reported so far.
The next step was to investigate the effects of large aro-
matic sidechains on the three catalytic activities when
placed in P4. In a recent study of peptide vinyl sulfones,
the presence and size of this sidechain had a substantial
impact on the reactivity against all three catalytic activi-
ties [25]. To address the structural requirements of the
P4 pocket in somewhat greater detail, we included
the building blocks homophenylalanine and p-ben-
zoylphenylalanine, in addition to alanine, leucine, pheny-
lalanine and 3-(1-naphthyl)-alanine, which were used for
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Table 1
Kinetic constants for inhibition of three catalytic activities of the proteasome by peptide α′,β′-epoxyketones of different length.
kobs/[I] (M–1s–1)*
Chymotrypsin-like activity Trypsin-like activity PGPH activity
Suc-LLVY-AMC Boc-LRR-AMC Z-LLE-AMC
1 14,000 (50–150 nM) —† 9.2 (100–160 µM)
2 780 (1–2.5 µM) 5.1 (100–150 µM) 120 (8–12 µM)
3 3.1 (100–160 µM) –† –†
4 –† –† –†
*See the Materials and methods section for details. †Inhibition at 150 µM was either absent or insufficient to allow curve-fit to the collected data. 
N
H
H
NN
H
H
N O
O
O
O
O
O
N
H
H
NN
H
O
O
O
O
O
N
H
H
N O
O
O
O
N
H
O
O
O
the compounds in Table 2. The resulting set of P4
analogs (compounds 11–15, Table 3) all showed strong
inhibition of the chymotrypsin-like activity with a clear
sidechain size optimum. Compound 11, containing an
alanine in P4, had a lower kobs/[I] value than the
tetraleucine inhibitor 1 for the inhibition of the chy-
motrypsin-like activity. Inhibitors 12–15 with aromatic
sidechains in P4 all exhibited improved inhibition of the
chymotrypsin-like activity with kobs/[I] in the same order
of magnitude as epoxomicin (Table 4) [22]. Homopheny-
lalanine in P4 (13) proved to be the most active inhibitor
with similar potency to compound 6 (Table 2), which
contains a phenylalanine residue in P2. These data,
however, do not reveal any clear trends for the trypsin-
like and PGPH activities for which the inhibitors are
either poor or inactive. Introduction of large aromatic
sidechains, as in compounds 14 and 15 with 3-(1-
naphtyl)-alanine and p-benzoylphenylalanine in P4,
resulted in inactive derivatives, whereas the alanine,
phenylalanine and homophenylalanine inhibitors 11–13
caused a modest reduction of the trypsin-like and PGPH
activities. Inhibition of the PGPH activity appeared to
benefit from small sidechain residues, that is the alanine
derivative 11, which is somewhat more active than the P3
alanine inhibitor 8 (Table 2). The ranking of compounds
1 and 11–15 (Table 3) is based on data collected with 20S
bovine erythrocyte proteasome. Investigating these
inhibitors with 20S proteasome from bovine brain
resulted in the same ranking and similar absolute kobs/[I]
values (data not shown).
The data in Tables 2 and 3 clearly indicate that the
potency of tetrapeptide α′,β′-epoxyketones for inhibition
of the chymotrypsin-like activity is enhanced by introduc-
tion of aromatic sidechains in P2–P4. Several of the com-
pounds, most notably 6 and 13 (Tables 2 and 3) are
excellent inhibitors of the chymotrypsin-like activity. Our
results, however, suggest that for this class of inhibitors,
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Table 2
Kinetic constants for inhibition of three catalytic activities of the proteasome by peptide α′,β′-epoxyketones with various amino
acids in P2 and P3.
kobs/[I] (M–1s–1)*
Chymotrypsin-like activity Trypsin-like activity PGPH activity
Suc-LLVY-AMC Boc-LRR-AMC Z-LLE-AMC
1 14,000 (50–150 nM) —† 9.2 (100–160 µM)
5 16,000 (80–120 nM) 4.1 (100–150 µM) 20 (60–80 µM)
6 54,000 (40–60 nM) —† —†
7 29,000 (60–120 nM) —† —†
8 1300 (500–1000 nM) 2.0 (120–150 µM) 130 (10–16 µM)
9 8500 (200–400 nM) —† —†
10 31,000 (40–100 nM) —† —†
*See the Materials and methods section for details. †Inhibition at 150 µM was either absent or insufficient to allow curve-fit to the collected data
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that is peptide α′,β′-epoxyketones with leucine in P1,
improvement of inhibition of the trypsin-like and PGPH
activities and simultaneous reduction of inhibition of the
chymotrypsin-like activity might be difficult to achieve. 
Synthesis and evaluation of an optimized inhibitor
The results in Table 1–3 clearly show that variation of
residues in P2–P4 of peptide α′,β′-epoxyketones with
leucine in P1 have a major impact on inhibition of the
chymotrypsin-like activity. Our efforts next focused on
the synthesis of a second generation inhibitor with
increased inhibition of the chymotrypsin-like activity.
Phenylalanine in P2 (6, Table 2) and homophenylalanine
in P4 (13, Table 3) showed major enhancements in
potency, so inhibitor 16 (Table 4) with a combination of
these residues was prepared. As expected, compound 16
was found to exhibit remarkable selectivity and potency
for inhibition of the chymotrypsin-like activity. Moreover,
compound 16 is more powerful and selective for the chy-
motrypsin-like activity than the previously characterized
inhibitors epoxomicin [22], dihydroeponemycin [23], the
boronic acid PS-341 [16], clasto-lactacystin β-lactone [15]
and NLVS [25,26] (Table 4). 
Because epoxomicin selectively targets the proteasome
without concomitant inhibition of other proteases such as
trypsin, chymotrypsin, papain, calpain and cathepsin B at
concentrations up to 50 µM [22], it can be assumed that
the peptide α′,β′-epoxyketone 16 exhibits a similar selec-
tivity pattern. Roush et al. [41] recently described the syn-
thesis and evaluation of two N-protected dipeptide
α′,β′-epoxyketones with excellent activity against the cys-
teine protease cruzain. Interestingly, inhibitors with
2-(S)-stereochemistry of the epoxide were found to be
substantially more active than the corresponding
2-(R)-derivatives. However, potent proteasome inhibitors
in this and previous studies [20–23] exclusively have the
2-(R)-configuration. In two investigations, the corre-
sponding 2-(S)-derivatives were tested and found to be
considerably less potent for inhibition of the proteasome
[20,21]. Apparently, the stereochemistry of the epoxide
plays an important role in selectivity for the proteasome
over other proteases.
To date, the most detailed investigation of sidechain
effects on proteasome specificity was carried out with P4
variants of peptide vinyl sulfones [25]. The inhibitors
816 Chemistry & Biology 1999, Vol 6 No 11
Table 3
Kinetic constants for inhibition of three catalytic activities of the proteasome by peptide α′,β′-epoxyketones with various amino
acids in P4.
kobs/[I] (M–1s–1)*
Chymotrypsin-like activity Trypsin-like activity PGPH activity
Suc-LLVY-AMC Boc-LRR-AMC Z-LLE-AMC
11 5300 (400–800 nM) 3.8 (100–150 µM) 220 (8–12 µM)
1 14,000 (50–100 nM) —† 9.2 (100–160 µM)
12 37,000 (40–80 nM) 5.5 (100–150 µM) 78 (20–40 µM)
13 63,000 (40–80 nM) 5.4 (120–150 µM) 50 (30–50 µM)
14 29,000 (60–120 nM) —† —†
15 23,000 (90–150 nM) —† —†
*See the Materials and methods section for details. †Inhibition at 150 µM was either absent or insufficient to allow curve-fit to the collected data.
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studied had a free amino terminus in order to mimic
peptide substrates that had already undergone one or more
cycles of hydrolytic cleavage. To address whether a free or
acetylated amino terminus of peptide α′,β′-epoxyketones
can effect subunit preference and potency, we prepared
compound 18 from the Fmoc protected precursor 17
(Figure 4). Evaluation of inhibitor 18 (Table 4), which is a
deacetylated derivative of the powerful inhibitor 16,
revealed a dramatic reduction in inhibition of the chy-
motrypsin-like activity indicating a subunit preference for
longer substrates or inhibitors. Compound 18 also exhib-
ited a major increase in potency for inhibition of the
trypsin-like activity with a higher kobs/[I] value than the
N-capped inhibitors (Tables 1–3), epoxomicin [22], epone-
mycin [23], NLVS [25] and clasto-lactacystin β-lactone [15]
(Table 4). Both 16 and 18 are weak inhibitors of the PGPH
activity (Table 4). The differences observed between
inhibitors 16 and 18 corroborate the results obtained in the
vinyl sulfone study in which uncapped inhibitors were less
potent against the chymotrypsin-like activity and more
active against the trypsin-like activity when compared
with NLVS [25]. It is interesting to speculate that the pro-
teolytic machinery of the proteasome may work in a
sequential manner, namely the chymotrypsin-like activity
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Table 4
Kinetic constants for inhibition of three catalytic activities of the proteasome by 16, 18, epoxomicin, PS-341, NLVS, and
clasto-lactacystin β-lactone.
kobs/[I] (M–1s–1)*
Chymotrypsin-like activity Trypsin-like activity PGPH activity
Suc-LLVY-AMC Boc-LRR-AMC Z-LLE-AMC
16 166,000 (5–12 nM) 7.1 (80–130 µM) 21 (80–150 µM)
18 5200 (0.11 µM) 580 (0.5–5 µM) 11 (10–150 µM)
37,000 (30–80 nM) 79 (8–12 µM) 37 (50–100 µM)
53,000 (30–10 nM) 150 (5–35 µM) 3200 (0.3–1 µM)
5000 (200–500 nM) 3.4 (50–120 µM) 4.0 (50–100 µM)
7400 (150–500 nM) 68 (8–12 µM) 47 (30–80 µM)
*See the Materials and methods section for details.
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cleaves initial longer substrates followed by continued
hydrolysis of the resulting shorter peptides by the trypsin-
like and PGPH activities. This argument is, in part, sup-
ported by the fact that shorter inhibitors such as the
trileucine compound 2 (Table 1), dihydroeponemycin
[23], and the dipeptidyl boronic acid PS-341 [16] (Table 4)
can inhibit the PGPH activity and, in some cases, do so
better than longer inhibitors.
The data for our novel peptide α′,β′-epoxyketones pre-
sented in Tables 1–4 reflect the importance of inhibitor
length and a clear cooperative effect of the sidechains in
different positions of peptide-based inhibitors with an
α′,β′-epoxyketone pharmacophore. Modifications, such as
the introduction of other amino acid residues in P1–P4,
addition of P1′ residues and a free amino terminus will
further add to our understanding of substrate recognition
by the 20S proteasome. Although introduction of polar or
charged residues and a free amino terminus might
enhance selectivity and potency for inhibition of the
trypsin-like and PGPH activities, these chemical modifi-
cations can be expected to result in lower membrane per-
meability, which is important for in vivo activity.
Correlation of inhibition of the chymotrypsin-like activity
and growth inhibition of bovine aortic endothelial cells
In this study, we demonstrate that peptide α′,β′-epoxyke-
tones with enhanced reactivity against the chymotrypsin-
like activity of the 20S proteasome can be prepared by
amino acid sidechain substitutions in P2–P4. In order to
address if these in vitro data can be translated to biological
function in vivo, inhibition of cell proliferation of bovine
aortic endothelial (BAE) cells was investigated with a
subset of our novel peptide α′,β′-epoxyketones. Prolifera-
tion of BAE cells was assayed in triplicate in the presence
of different concentrations of peptide α′,β′-epoxyketones.
After 5 days, all inhibitors consistently inhibited cell
growth in a dose-dependent manner. As illustrated in
Table 5 and Figure 5, a higher kobs/[I] value for inhibition
of the chymotrypsin-like activity of the proteasome gener-
ally corresponds to a lower IC50 value for inhibition of cell
proliferation. The absence of a strict correlation between
kobs/[I] and IC50 values most likely reflects the greater
818 Chemistry & Biology 1999, Vol 6 No 11
Figure 4
Synthesis of a peptide α′,β′-epoxyketone with an unprotected
amino terminus.
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Figure 5
Correlation of log kobs/[I] values for inhibition of the chymotrypsin-like
activity of the proteasome with log IC50 values for inhibition of bovine
aortic endothelial (BAE) cell proliferation by a subset of peptide
α′,β′-epoxyketones. 
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Table 5
Values of kobs/[I] for inhibition of the chymotrypsin-like activity
and IC50 values for inhibition of BAE cell proliferation for a
subset of peptide α′,β′-epoxyketones.
Inhibitor Kobs/[I] (M–1 s–1)* IC50 (nM)†
5 Ac-LLAL-epoxide 16,000 34
6 Ac-LLFL-epoxide 54,000 7
8 Ac-LALL-epoxide 1300 700
9 Ac-LFLL-epoxide 8500 16
11 Ac-ALLL-epoxide 5300 83
16 Ac-hFLFL-epoxide 166,000 20
*See the Materials and methods section for details. †Approximately
1000 BAE cells were plated into each well of a 96-well culture plate.
After an overnight incubation, different concentrations of proteasome
inhibitors were added and incubation was continued for another
5 days. Subsequently, [methyl-3H]-thymidine was added to the plate
and incubated for an additional 4 h. Cells were harvested and
incorporated radioactivity was quantified using liquid scintillation.
complexity of a cell-based assay than that of an in vitro
assay with purified proteasome. It is also possible that
inhibitors with lower kobs/[I] values cause substantial inhi-
bition of cellular proteasomes during experiments con-
ducted over longer times because the kobs/[I] values
indicate the rate of enzyme inactivation. Potent inhibitors
with kobs/[I] values greater than 8,000 M–1s–1 gave IC50
values in the range of 7–34 nM. The trend observed in
Figure 5 suggests that the proteasome is the true biologi-
cal target for this powerful class of inhibitors. 
Epoxomicin and Ac-hFLFL-epoxide (16) exhibit potent anti-
inflammatory activity in vivo
Haptens such as 2,4,6-trinitrochlorobenzene (picryl chlo-
ride) and 2,4-dinitrofluorobenzene (DNFB) elicit nonspe-
cific irritant sensitivity responses within 24 hours after
contact in the mouse ear edema assay [42]. On the basis of
our previous observation that epoxomicin potently inhib-
ited NF-κB activation in tumor necrosis factor α
(TNF-α)-stimulated cells and demonstration of in vivo
anti-inflammatory activity in the contact sensitivity assay
[22], we investigated the pharmacological activities of the
optimized inhibitor 16 in the DNFB ear edema model of
irritant sensitivity. Mice were injected with either a low
dose (0.32 mg/kg) or a high dose (2.0 mg/kg) of epoxo-
micin, the inhibitor 16 (0.37 and 2.3 mg/kg), or vehicle
(10% DMSO) one hour prior to applying DNFB to the
ear. The low dose corresponds to 0.58 µmol/kg and the
high dose to 3.6 µmol/kg for both epoxomicin and 16. Ear
thickness was measured at 0 and 24 hours after DNFB
application. As shown in Figure 6, a single dose of epox-
omicin at 2.0 mg/kg inhibited ear inflammation by nine-
fold over that of vehicle-treated controls. Interestingly, a
sixfold lower amount of epoxomicin decreased inflamma-
tion by this same margin. A low dose of optimized
inhibitor 16 also exerted potent anti-inflammatory activity,
reducing ear swelling by the same amount as epoxomicin.
At the higher dose, the inhibitor 16 decreased ear swelling
by 12-fold, demonstrating a small but higher level of
potency compared to epoxomicin. The natural product
epoxomicin and 16, which is optimized for inhibition of
the chymotrypsin-like activity of the proteasome, there-
fore, both exhibit potent anti-inflammatory activities in
vivo. Furthermore, these results indicate that for this class
of inhibitors strong in vitro proteasome inhibition corre-
lates with strong in vivo activities, as illustrated by the
anti-proliferative and anti-inflammatory activities. The
inhibitor 16 and the inhibitors used in the cell prolifera-
tion assays are selective for inhibition of the chy-
motrypsin-like activity suggesting that inhibition of this
activity is sufficient to cause a biological effect such as
growth arrest and anti-inflammatory activity in vivo. 
Significance
The proteasome is a multicatalytic proteolytic complex
responsible for ubiquitin-dependent protein degradation.
Given the importance of the proteasome in normal physi-
ological and disease states, compounds that inhibit the
proteasome in vitro and in vivo are needed as molecular
probes for understanding proteasome biology and as
potential therapeutic compounds. In addition to the bio-
logical potency, inhibitors should be selective for the pro-
teasome and preferably for one of the three major
proteasomal catalytic activities. In this study, we have
synthesized and evaluated a panel of peptide
α′,β′-epoxyketones based on the natural product epox-
omicin that exhibit antitumor and anti-inflammatory
activity through inhibition of the proteasome. All
inhibitors contained a leucine residue in the P1 position
and were found to be good or excellent inhibitors of the
chymotrypsin-like activity and poor inhibitors of the
trypsin-like and post-glutamyl peptide hydrolyzing
(PGPH) activities. Introduction of different aliphatic and
aromatic residues in P2–P4 had a dramatic impact on
the inhibition of the chymotrypsin-like activity. Inhibi-
tion of the chymotrypsin-like activity could be correlated
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Figure 6
Irritant sensitivity response to 2,4-dinitrofluorobenzene (DNFB). BALB/c
mice were injected with epoxomicin (0.32 mg or 2.0 mg/kg body
weight), inhibitor 16 (0.37 or 2.3 mg/kg body weight) or with vehicle
(10% DMSO in buffered saline) prior to ear challenge with 0.3% DNFB.
The low dose corresponds to 0.58 µmol/kg and the high dose to
3.6 µmol/kg for both epoxomicin and 16. Ear swelling measurements of
both ears were made 0 h and 24 h post-ear challenge with an
engineer’s micrometer. Results are expressed as 24 h ear thickness
measurement minus 0 h ear thickness measurement.
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with inhibition of cell proliferation indicating that the bio-
logical effect is mediated by proteasome inhibition. Opti-
mization furnished an inhibitor, Ac-hFLFL-epoxide,
that proved to be more potent and selective for inhibition
of the chymotrypsin-like activity than several previously
described inhibitors. Furthermore, the optimized
inhibitor exhibits strong anti-inflammatory activity in a
contact irritant sensitivity assay in mice. Taken together
our results show that amino acid substitutions in differ-
ent positions of proteasome inhibitors can be used to
enhance both in vitro and in vivo activity of peptide
α′,β′-epoxyketones. This family of inhibitors constitutes a
valuable class of molecular probes for understanding
proteasome biology and as therapeutic agents that target
proteasome functions in different stages of disease.
Materials and methods
General
Peptides were synthesized by standard solid-phase peptide synthe-
sis [37,38] starting from commercially available Nα-fluoren-9-yl-
methoxycarbonyl (Fmoc) amino acid Wang resins except for the
peptide with 3-(1-naphtyl)-alanine as carboxy-terminal amino acid,
which was synthesized from a 2-chlorotrityl chloride resin. Nα-Fmoc
and Nα-acetyl amino acids were coupled in DMF with O-benzotriazol-
1-yl-N,N,N,N′-tetramethyluronium hexafluorophosphate (HBTU) and
DIEA, or HATU and DIEA. Fmoc groups were removed with 20%
piperidine in DMF and final cleavage from the solid support was
effected by trifluoroacetic acid:water (95:5). DMF was distilled under
reduced pressure and stored over 4 Å molecular sieves.
Dichloromethane was passed through a short column of neutral
Al2O3 (activity 1) and stored over 4 Å molecular sieves. Flash column
chromatography was performed with EM Science silica gel 60
(230–400 mesh) and thin layer chromatography (TLC) was carried
out with Merck silica gel 60 (0.25 mm) F254 precoated glass plates
with appropriate hexanes-ethylacetate or dichloromethane-methanol
systems. TLC plates were stained by heating with phosphomolybdic
acid in ethanol. Preparative HPLC was performed with a Rainin
Dynamax system with a Microsorb silica column (100 Å, 5 µm,
21.4 × 250 mm) and UV detection (214 nm) with appropriate gradi-
ents of isopropanol in hexanes (15—20 ml/min). 1H-NMR spectra
were recorded with a Bruker AM-500 spectrometer at 500 MHz in
CDCl3 (δH 7.27), acetone-d6 (δH 2.05) or DMSO-d6 (δH 2.49). Elec-
trospray (ES) mass spectra were recorded at the Yale Cancer Center
Mass Spectrometry Resource and the W.M. Keck Foundation
Biotechnology Resource Laboratory, New Haven, CT, USA. In addi-
tion to signals corresponding to (M + H)+, signals originating from
(M + Na)+ and (M + K)+ were frequently observed. Epoxomicin
(Figure 1) and the right-hand fragment (2R,4S)-4-amino-2,6-dimethyl-
hept-1,2-epoxy-3-one (Figure 3b) were prepared essentially as
described previously [21]. Fmoc amino acids and resins were pur-
chased from Advanced ChemTech and HATU from PerSeptive
Biosystems. NLVS and clasto-lactacystin β-lactone were obtained
from CalBiochem and 2,4-dinitrofluorobenzene (DNFB) was pur-
chased from Sigma Chemical Co. Proteasome substrates were
obtained from Bachem and Peptides International. [Methyl-3H]-thymi-
dine was purchased from NEN Science Products, Inc.
General protocol for synthesis of peptide α′,β′-epoxyketones
The left-hand peptide fragment (104 µmol, Figure 3a) was dissolved in
DMF (0.2–0.3 ml) and the trifluoroacetate ammonium salt of (2R,4S)-4-
amino-2,6-dimethyl-hept-1,2-epoxy-3-one (15 mg, 52 µmol, Figure 3b)
in dichloromethane (1.5 ml) was added. Collidine (2,4,6-trimethylpyri-
dine, 26 µl, 208 µmol) and HATU (40 mg, 104 µmol) were added and
the resulting mixture was stirred at room temperature. After 3–4 h the
solution was concentrated under reduced pressure and the residue was
flash chromatographed (dichloromethane–methanol) to give partially
purified product. The peptide α′,β′-epoxyketone was isolated (typically
> 95% purity in 20–70% yield) by preparative normal phase HPLC (gra-
dient of isopropanol in hexanes).
Selected 1H-NMR and ESMS data for compounds 1–17
1: 1H-NMR δ (DMSO-d6) 8.04 (d, J = 7.0 Hz, 1 H), 8.00 (d, J = 8.5 Hz,
2 H), 7.70 (d, J = 9.0 Hz, 1 H), 4.34–4.20 (m, 4 H), 3.17 (d, J = 5.5 Hz,
1 H), 2.99 (d, J = 5.0 Hz, 1 H), and 1.81 (s, 3 H); ESMS (M + H)+
calc’d 553.40, found 553.35.
2: 1H-NMR δ (DMSO-d6) 7.99 (d, J = 7.5 Hz, 1 H), 7.95 (d, J = 8.0 Hz,
1 H), 7.84 (d, J = 9.0 Hz, 1 H),4.39–4.23 (m, 3 H), 3.16 (d, J = 5.0 Hz,
1 H), 2.98 (d, J = 5.0 Hz, 1 H), and 1.81 (s, 3 H); ESMS (M + H)+
calc’d 440.31, found 440.39.
3: 1H-NMR δ (CDCl3) 6.35 (d, J = 7.5 Hz, 1 H), 5.89 (d, J = 8.0 Hz,
1 H), 4.56 (ddd, J = 3.1, 7.4, and 10.4 Hz, 1 H), 4.46 (ddd, J = 5.5
and 8.5 Hz, 1 H), 3.30 (d, J = 5.0 Hz, 1 H), 2.90 (d, J = 5.5 Hz, 1 H),
1.99 (s, 3 H), and 1.52 (s, 3 H); ESMS (M + H)+ calc’d 327.23,
found 327.27.
4: 1H-NMR δ (CDCl3) 5.80–5.75 (m, 1 H), 4.68–4.64 (m, 1 H), 3.35
(d, J = 4.5 Hz, 1 H), 2.90 (d, J = 5.0 Hz, 1 H), 1.99 (s, 3 H), 1.52 (s,
3 H), 0.98 (d, J = 7.0 Hz, 3 H), and 0.95 (d, J = 6.5 Hz, 3 H); ESMS
(M + H)+ calc’d 214.15, found 214.17.
5: 1H-NMR δ (DMSO-d6) 8.07 (d, J = 7.5 Hz, 1 H), 7.96 (d, J = 8.0 Hz,
1 H), 7.91 (d, J = 8.5 Hz, 1 H), 7.73 (d, J = 7.0 Hz, 1 H), 4.34–4.29 (m,
1 H), 4.27–4.20 (m, 3 H), 3.17 (d, J = 5.5 Hz, 1 H), 3.00 (d, J = 5.0 Hz,
1 H), 1.82 (s, 3 H), 1.39 (s, 3 H), and 1.14 (d, J = 7.0 Hz, 3 H); ESMS
(M + H)+ calc’d 511.35, found 511.44.
6: 1H-NMR δ (DMSO-d6) 8.19 (d, J = 7.0 Hz, 1 H), 7.95 (d, J = 8.0 Hz,
1 H), 7.89 (d, J = 8.5 Hz, 1 H), 7.72 (d, J = 8.0 Hz, 1 H), 7.23–7.14 (m,
5 H), 4.53–4.48 (m, 1 H), 4.38–4.33 (m, 1 H), 4.24–4.15 (m, 2 H),
3.14 (d, J = 6.0 Hz, 1 H), 2.98 (d, J = 5.5 Hz, 1 H), 2.96 (dd, J = 5.0
and 16.0 Hz, 1 H), 2.74 (dd, J = 8.8 and 13.8 Hz, 1 H), 1.81 (s, 3 H),
and 1.39 (s, 3 H); ESMS (M + H)+ calc’d 587.38, found 587.50.
7: 1H-NMR δ (DMSO-d6) 8.15 (bt, J = 6.8 Hz, 2 H), 7.98 (d, J = 8.0 Hz,
1 H), 7.93 (d, J = 7.5 Hz, 1 H), 7.89 (bt, J = 7.0 Hz, 2 H), 7.76 (d,
J = 8.0 Hz, 1 H), 7.57–7.49 (m, 2 H), 7.35 (t, J = 7.8 Hz, 1 H), 7.27 (d,
J = 7.0 Hz, 1 H), 4.67—4.63 (m, 1 H), 4.41–4.36 (m, 1 H), 4.24–4.13
(m, 2 H), 3.43 (dd, J = 5.5 and 14.5 Hz, 1 H), 3.20–3.16 (m, 2 H), 3.00
(d, J = 5.0 Hz, 1 H), and 1.82 (s, 3 H); ESMS (M + H)+ calc’d 637.40,
found 637.55.
8: 1H-NMR δ (DMSO-d6) 8.07 (d, J = 7.0 Hz, 1 H), 8.06 (d, J = 7.0 Hz,
1 H), 7.98 (d, J = 8.0 Hz, 1 H), 7.62 (d, J = 8.5 Hz, 1 H), 4.33–4.19 (m,
4 H), 3.17 (d, J = 5.0 Hz, 1 H), 2.99 (d, J = 5.5 Hz, 1 H), 1.82 (s, 3 H),
1.38 (s, 3 H), and 1.16 (d, J = 7.5 Hz, 3 H); ESMS (M + H)+ calc’d
511.35, found 511.46.
9: 1H-NMR δ (DMSO-d6) 8.13 (d, J = 6.5 Hz, 1 H), 7.97 (d, J = 8.0 Hz,
1 H), 7.95 (d, J = 10.0 Hz, 1 H), 7.80 (d, J = 8.5 Hz, 1 H), 7.22–7.14
(m, 5 H), 4.48–4.43 (m, 1 H), 4.34–4.28 (m, 2 H), 4.18 (bdd, J = 7.5
and 15.5 Hz, 1 H), 3.19 (d, J = 5.0 Hz, 1 H), 3.04–2.98 (m, 1 H), 2.79
(dd, J = 9.2 and 13.8 Hz, 1 H), 1.78 (s, 3 H), and 1.39 (s, 3 H); ESMS
(M + H)+ calc’d 587.38, found 587.51.
10: 1H-NMR δ (DMSO-d6) 8.14 (d, J = 8.5 Hz, 1 H), 8.11 (d,
J = 8.5 Hz, 1 H), 8.07 (d, J = 7.0 Hz, 1 H), 7.90 (bt, J = 8.2 Hz, 2 H),
7.77 (bt, J = 8.0 Hz, 2 H), 7.56–7.49 (m, 2 H), 7.36–7.31 (m, 2 H),
4.60 (ddd, J = 4.7 and 9.0 Hz, 1 H), 4.38–4.30 (m, 2 H), 4.15 (bdd,
J = 8.0 and 15.0 Hz, 1 H), 3.54 (dd, J = 5.0 and 14.5 Hz, 1 H), 3.21
(dd, J = 10.0 and 15 Hz, 1 H), 3.19 (d, J = 5.5 Hz, 1 H), 2.99 (d,
J = 5.5 Hz, 1 H), 1.78 (s, 3 H), and 1.39 (s, 3 H); ESMS (M + H)+
calc’d 637.40, found 637.52.
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11: 1H-NMR δ (DMSO-d6) 8.03–8.02 (m, 2 H), 7.90 (d, J = 8.0 Hz,
1 H), 7.71 (d, J = 8.5 Hz, 1 H), 4.34–4.19 (m, 4 H), 3.16 (d, J = 5.0 Hz,
1 H), 2.99 (d, J = 5.5 Hz, 1 H), 1.81 (s, 3 H), 1.38 (s, 3 H), and 1.14 (d,
J = 7.5 Hz, 3 H); ESMS (M + H)+ calc’d 511.35, found 511.29.
12: 1H-NMR δ (DMSO-d6) 8.08–8.03 (m, 3 H), 7.81 (d, J = 8.5 Hz,
1 H), 7.24–7.23 (m, 4 H), 7.18–7.16 (m, 1 H), 4.48 (ddd, J = 4.0, 8.2,
and 9.8 Hz, 1 H), 4.35–4.25 (m, 3 H), 3.14 (d, J = 5.0 Hz, 1 H), 2.96
(d, J = 5.5 Hz, 1 H), 2.95 (dd, J = 4.0 and 12.8 Hz, 1 H), 2.69 (dd,
J = 9.8 and 13.8 Hz, 1 H), 1.73 (s, 3 H), and 1.38 (s, 3 H); ESMS
(M + H)+ calc’d 587.38, found 587.24.
13: 1H-NMR δ (DMSO-d6) 8.09 (d, J = 8.0 Hz, 1 H), 8.02 (d,
J = 7.0 Hz, 1 H), 7.99 (d, J = 8.5 Hz, 1 H), 7.77 (d, J = 9.0 Hz, 1 H),
7.27–7.15 (m, 5 H), 4.32–4.22 (m, 4 H), 3.13 (d, J = 5.0 Hz, 1 H),
2.96 (d, J = 5.0 Hz, 1 H), 2.57–2.50 (m, 2 H), 1.85 (s, 3 H), and 1.38
(s, 3 H); ESMS (M + H)+ calc’d 601.40, found 601.38.
14: 1H-NMR δ (DMSO-d6) 8.17 (d, J = 7.5 Hz, 2 H), 8.12 (d,
J = 8.0 Hz, 1 H), 8.09 (d, J = 6.5 Hz, 1 H), 7.9 (bd, J = 7.5 Hz, 1 H),
7.81 (d, J = 8.0 Hz, 1 H), 7.77 (bt, J = 4.8 Hz, 1 H), 7.56–7.50 (m,
2 H), 7.40–7.38 (m, 2 H), 4.68–4.64 (m, 1 H), 4.36–4.30 (m, 3 H),
3.49 (dd, J = 4.0 and 15.0 Hz, 1 H), 3.13 (dd, J = 9.5 and 14.0 Hz,
1 H), 3.12 (d, J = 5.0 Hz, 1 H), 2.91 (d, J = 5.5 Hz, 1 H), 1.71 (s, 3 H),
and 1.37 (s, 3 H); ESMS (M + H)+ calc’d 637.40, found 637.35.
15: 1H-NMR δ (acetone-d6) 7.77–7.76 (m, 2 H), 7.71 (bd, J = 8.0 Hz,
2 H), 7.68–7.64 (m, 2 H), 7.57–7.52 (m, 3 H), 7.47–7.43 (m, 3 H),
7.34 (d, J = 7.0 Hz, 1 H), 4.70–4.66 (m, 1 H), 4.54–4.50 (m, 1 H),
4.45–4.37 (m, 2 H), 3.31 (d, J = 5.0 Hz, 1 H), 3.27 (dd, J = 5.0 and
14.0 Hz, 1 H), 3.11 (dd, J = 7.8 and 13.8 Hz, 1 H), 2.92 (d, J = 5.5 Hz,
1 H), 1.91 (s, 3 H), and 1.43 (s, 3 H); ESMS (M + H)+ calc’d 691.41,
found 691.38.
16: 1H-NMR δ (DMSO-d6) 8.21 (d, J = 7.5 Hz, 1 H), 8.10 (d,
J = 8.0 Hz, 1 H), 7.96 (d, J = 8.0 Hz, 1 H), 7.84 (d, J = 8.0 Hz, 1 H),
7.23 (bt, J = 7.5 Hz, 2 H), 7.20–7.06 (m, 8 H), 4.51 (ddd, J = 4.8 and
8.8 Hz, 1 H), 4.36–4.31 (m, 1 H), 4.24–4.19 (m, 2 H), 3.09 (d,
J = 5.5 Hz, 1 H), 2.95 (dd, J = 4.5 and 14.0 Hz, 1 H), 2.94 (d,
J = 4.5 Hz, 1 H), 2.73 (dd, J = 9.2 and 14.2 Hz, 1 H), 2.58–2.46 (m,
2 H), 1.85 (s, 3 H), 1.38 (s, 3 H), 0.86 (d, J = 6.5 Hz, 3 H), 0.83 (d,
J = 7.0 Hz, 3 H), and 0.78 (bt, J = 6.8 Hz, 6 H); ESMS (M + H)+ calc’d
635.38, found 635.40.
17: 1H-NMR δ (acetone-d6) 7.87 (d, J = 7.5 Hz, 2 H), 7.70 (dd, J = 7.8
and 11.2 Hz, 2 H), 7.60 (bs, 1 H), 7.47 (d, J = 8.5 Hz, 1 H),
7.74–7.08 (m, 11 H), 7.00 (bs, 1 H), 4.64 (ddd, J = 4.7 and 8.6 Hz,
1 H), 4.56–4.46 (m, 2 H), 4.38–4.24 (m, 3 H), 4.16 (dd, J = 6.0 and
13.5 Hz, 1 H), 3.28 (d, J = 5.0 Hz, 1 H), 3.20 (dd, J = 4.8 and
14.2 Hz, 1 H), 2.91 (d, J = 5.5 Hz, 1 H), 2.90 (dd, J = 5.0 and
16.2 Hz, 1 H), 2.78–2.66 (m, 2 H), 1.44 (s, 3 H), 0.87 (bt, J = 6.0 Hz,
6 H), and 0.82 (bt, J = 6.2 Hz, 6 H); ESMS (M + H)+ calc’d 815.44,
found 815.47.
Synthesis of compound 18
Compound 17 (11 mg, 13.5 µmol) was dissolved in tetrahydrofuran
(1 ml) and tetrabutylammonium fluoride (40 µl, 20 µmol, 0.5 M in
tetrahydrofuran) was added. The resulting solution was stirred at room
temperature for 70 min. Approximately half of the solvent was removed
by evaporation under reduced pressure and the remaining solution was
chromatographed (dichloromethane–methanol, 20:1) to give 18
(5.2 mg, 65% yield). Selected 1H-NMR data δ (acetone-d6) 7.50 (d,
J = 8.0 Hz, 1 H), 7.44 (d, J = 8.0 Hz, 1 H), 7.33 (d, J = 8.0 Hz, 1 H),
7.27–7.14 (m, 10 H), 4.63 (ddd, J = 5.1 and 8.2 Hz, 1 H), 4.56 (ddd,
J = 3.8, 7.8, and 10.0 Hz, 1 H), 4.44–4.40 (m, 1 H), 3.89 (bt, J = 6.0
Hz, 1 H), 3.28 (d, J = 5.0 Hz, 1 H), 3.11 (dd, J = 5.5 and 14.0 Hz, 1 H),
2.95 (d, J = 5.0 Hz, 1 H), 2.88 (dd, J = 8.2 and 14.2 Hz, 1 H),
2.63–2.57 (m, 2 H), and 1.45 (s 3 H); ESMS (M + H)+ calc’d 592.37,
found 593.49.
Purification of 20S proteasome 
20S proteasome was purified from bovine reticulocyte lysate by batch
DE-52 binding, DEAE-Sephacel chromatography, gel filtration on
Sephacryl S-300, and chromatography on hydroxyapatite. This proce-
dure was essentially adopted from a previous procedure [43,44],
except that bovine reticulocytes were used as a starting source.
Enzyme kinetic assays
The desired inhibitor and peptide 7-aminomethyl coumarin (AMC) sub-
strate in DMSO (Suc–LLVY–AMC, final assay concentration 5 µM;
Z–LLE–AMC, final assay concentration 5 µM; Boc–LRR–AMC, final
assay concentration 10 µM) were added to 50 µl assay buffer (20 mM
Tris–HCl, pH 8.0, 0.5 mM EDTA; for Suc–LLVY–AMC and
Z–LLE–AMC, 0.035% sodium dodecyl sulfate (SDS) was included)
and the assay was started by addition of 50 µl assay buffer containing
bovine erythrocyte 20S proteasome. The assays were performed at
room temperature (22–26°C) in Dyn-Ex Microfluor® 96-well plates and
the fluorescence emission was measured at 460 nm (λex = 360 nm)
using a Cytofluor fluorescence plate reader. Values for kobs/[I] were
obtained with the program Kaleidagraph by nonlinear least square fit of
the data following the equation for slow and tight binding inhibition
[45]: Fluorescence = vst + [(v0–vs)/kobs][1–exp(–kobst)], were v0 and vs
are the initial and final velocity respectively, and kobs is the reaction rate
constant. The values for kobs/[I] given in Tables 1–4 represent an
average of typically nine measurements (generally three independent
experiments with three different inhibitor concentrations). Peptide
α′,β′-epoxyketones exhibiting low or no inhibition at 150 µM were not
tested at higher concentrations in order to avoid problems with low sol-
ubility. It is assumed that kobs/[I] values for these compounds are low
compared with inhibitors that allow curve-fit to data collected at con-
centrations lower than 150 µM.
Cell proliferation assays
BAE cells were cultured at 7% CO2 and were grown in DMEM supple-
mented with 10% FBS, 1% penicillin/streptomycin (GIBCO), and
1 mM sodium pyruvate. Approximately 1000 cells were plated into
each well of a 96-well culture plate. After an overnight incubation, dif-
ferent concentrations of proteasome inhibitors were added and incuba-
tion was continued for another 5 days. Subsequently, 74 kBq of
[methyl-3H]-thymidine was added to each well and the plate was incu-
bated for an additional 4 h. Cells were harvested using a Skatron Cell
Harvester and incorporated radioactivity was quantified using liquid
scintillation. Each inhibitor concentration was evaluated in triplicate.
Assay for irritant sensitivity 
Irritant sensitivity response assays to DNFB was performed essen-
tially as described previously [46], with slight modifications. In brief,
0-hour ear thickness measurements of both ears were made in tripli-
cate with an engineer's micrometer (Peacock dial thickness gauge,
Ozaki Manufacturing Co., LTD., Japan). Five mice per group were
subsequently injected intraperiteoneally with epoxomicin (0.32 or
2.0 mg/kg body weight) or with the optimized inhibitor 16 (0.37 or
2.3 mg/kg body weight) in 10% DMSO-phosphate buffered saline.
The low dose corresponds to 0.58 µmol/kg and the high dose to
3.6 µmol/kg for both epoxomicin and 16. The control group of mice
received an equal volume of the vehicle (10% DMSO-phosphate
buffered saline). After 1 h, mice were challenged on both ear lobes by
application of 10 µl of a 0.2% solution of DNFB in acetone:high-
grade extra virgin olive oil, 4:1. Ear swelling measurements were
made in triplicate 24 h after ear challenge. 
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